Simple Summary Liquid biopsy has recently been introduced as a novel method in cancer
diagnostics. It is less invasive for patients than conventional tissue biopsies, as the assay …

Non-small cell lung cancer (NSCLC) presents the greatest number of identified therapeutic
targets, some of which have therapeutic utility. Currently, detecting EGFR, BRAF, KRAS and …

Introduction Most published guidelines for genomic biomarker testing in NSCLC reflect the
disease epidemiology and treatments readily available in Europe and North America …

Simple Summary Osimertinib has revolutionized the treatment of EGFR-mutated tumors. Its
current applications include the first-line setting, second-line setting, as well as the adjuvant …

The increasing number of approved drugs along with next generation sequencing (NGS)
technologies look out as potential revolution of biomolecular characterization of non-small …

Simple Summary Genomic profiling of non-small cell lung cancer (NSCLC) patients offers
the possibility of therapeutic intervention with target-based agents. The analysis of …

HER2 mutations, which account for 2–4% of non-small cell lung cancer (NSCLC), are
distinct molecular alterations identified via next generation sequencing (NGS). Previously …

Objective Panel-based next-generation sequencing (NGS) is increasingly used for the
diagnosis of EGFR-mutated non-small-cell lung cancer (NSCLC) and could improve risk …

Anti‐human epidermal growth factor receptor 2 (HER2) therapy is an effective treatment for
HER2‐positive gastric and breast malignancies. However, the efficacy of HER2‐targeted …

PURPOSE HER2-altered non–small-cell lung cancer (NSCLC) represents a diverse
subgroup, including mutations, amplifications, and overexpression. However, HER2 exon 20 …